- IRIDEX (NASDAQ: IRIX)‘s CFO Dizon Romeo R increased his stake by purchasing 5,004 shares, bringing his total holdings to 126,004 shares.
- The medical technology company reported a narrower net loss of 3 cents per share in Q1 2026, a significant improvement from 10 cents per share loss year-over-year, driven by reduced operating expenses.
- Despite the improved net loss, total revenues for the quarter declined 1% to $11.8 million, leading to a contraction in gross margin from 43% to 40% due to weaker retina product sales and supply-chain issues.
A recent filing for IRIDEX (NASDAQ: IRIX) shows Chief Financial Officer Dizon Romeo R purchasing 5,004 shares at $1.00 each. This transaction increases the officer’s total holdings in the company to 126,004 shares. This move comes as the company navigates a mixed financial landscape following its first-quarter 2026 earnings report.
IRIDEX is a medical technology company that develops, manufactures, and markets laser-based medical systems. These systems are used in ophthalmology to treat serious eye diseases. The company focuses on innovative treatments for glaucoma and various retinal diseases, serving a specialized segment of the global healthcare industry.
The insider purchase follows first-quarter results where IRIDEX shows a narrower net loss. As highlighted by Zacks, the net loss is 3 cents per share, a significant improvement from the 10 cents per share loss in the same period last year. This is supported by better cost control, with operating expenses decreasing 4% to $5.1 million.
Despite the smaller loss, total revenues for the quarter decline 1% to $11.8 million. This is mainly because of weaker sales from its retina products and supply-chain problems. As a result, the company’s gross margin, which is the profit made on sales before operating costs, contracts to 40% from 43% a year earlier.
A breakdown of sales shows strong performance in glaucoma products. As reported by GlobeNewswire, revenue from the Cyclo G6 product family grows 14% to $3.6 million, driven by higher probe sales. In contrast, revenue from the company’s retina products declines to $5.8 million from $6.6 million in the prior year.
